Thermo Fisher Scientific (TMO) EBIT (2009 - 2025)

Thermo Fisher Scientific has disclosed EBIT across 17 years of filings, most recently posting $7.7 billion for FY2025.

• Quarterly EBIT rose 8.57% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 billion (up 6.81% YoY) and the FY2025 annual result came in at $7.7 billion, up 5.57% from the prior year.
• EBIT improved to $7.7 billion in FY2025, from $7.3 billion in the prior year.
• Over five years, EBIT peaked at $10.0 billion in FY2021 and troughed at $6.9 billion in FY2023.
• A 5-year average of $8.1 billion and a median of $7.7 billion in 2025 frame the typical range for EBIT.
• Annual changes were most pronounced in 2021 — EBIT gained 28.66% — and 2023, when it dropped 18.28%.
• Tracing TMO's EBIT over 5 years: stood at $10.0 billion in 2021, then declined by 16.3% to $8.4 billion in 2022, then decreased by 18.28% to $6.9 billion in 2023, then gained by 6.97% to $7.3 billion in 2024, then rose by 5.57% to $7.7 billion in 2025.
• Business Quant data shows TMO's EBIT at $7.7 billion in FY2025, $7.3 billion in FY2024, and $6.9 billion in FY2023.